Latest News on OFIX

Financial News Based On Company


Advertisement
Advertisement

Orthofix Medical (OFIX) Stock Sees Fair Value Cut After Analysts Rework Q3 Risks

https://sg.finance.yahoo.com/news/orthofix-medical-ofix-stock-sees-141048878.html
Analysts have cut their fair value and price targets for Orthofix Medical (OFIX) stock, revising them to a tighter US$9 to US$10 range. This adjustment is attributed to Q3 revenue, adjusted EBITDA, and cash flow shortfalls, along with a reevaluation of execution risks. While Barrington maintains an "Outperform" rating, both Barrington and TD Cowen lowered their price targets, signaling ongoing concerns about near-term growth and profitability.

An investment manager reports zero shares in Orthofix Medical (OFIX) as of September 30, 2026.

https://www.stocktitan.net/sec-filings/OFIX/schedule-13g-a-orthofix-medical-inc-amended-passive-investment-disclo-bec83f305159.html
Armistice Capital, LLC and its managing member, Steven Boyd, reported zero beneficial ownership of Orthofix Medical Inc. (OFIX) common shares as of September 30, 2026. This Schedule 13G/A filing indicates that neither Armistice Capital nor Steven Boyd held any voting or dispositive power over OFIX shares. The filing specifies 0.00% ownership, reinforcing their complete divestment or lack of prior holdings in the company.

Form 4 Orthofix Medical Inc: Juniper Investment Company, LLC (10% Owner) For: 9 November By Investing.com

https://ca.investing.com/news/stock-market-news/form-4-orthofix-medical-inc-juniper-investment-company-llc-10-owner-for-9-november-93CH-4955390
This article reports on a Form 4 filing for Orthofix Medical Inc., indicating that Juniper Investment Company, LLC, a 10% owner, made a transaction on November 9. The report is a standard disclosure for significant ownership changes or insider transactions, providing transparency for investors.

About $8.27M in open-market buys add to Juniper's Orthofix Medical (OFIX) position.

https://www.stocktitan.net/sec-filings/OFIX/schedule-13d-a-orthofix-medical-inc-amended-major-shareholder-report-b7706b80ab90.html
Juniper Targeted Opportunity Fund, L.P. acquired 1,039,303 shares of Orthofix Medical Inc. (OFIX) for approximately $8.27 million in open-market purchases between August 14, 2026, and November 11, 2026. Following these transactions, the reporting persons collectively hold 5,481,846 shares, representing about a 13.4% beneficial ownership stake in Orthofix Medical. This information was disclosed in an amended SCHEDULE 13D/A filing with the SEC.

Orthofix Medical (OFIX) 10% owner Juniper Investment bought 689,803 shares for $5.11M at an average $7.40

https://www.quantisnow.com/insight/large-owner-juniper-investment-company-llc-bought-5106709-worth-of-6788912
Juniper Investment Company, a 10% owner of Orthofix Medical (OFIX), purchased 689,803 shares for $5.11 million at an average price of $7.40 per share. These open-market purchases, made between November 9 and November 11, 2026, increased Juniper Investment's indirect stake to approximately 4.46 million shares. This transaction was reported via a Form 4 filing and detailed individual purchases at prices ranging from $6.57 to $8.00.
Advertisement

TD Cowen cuts Orthofix Medical stock price target on supply issues

https://ca.investing.com/news/stock-market-news/td-cowen-cuts-orthofix-medical-stock-price-target-on-supply-issues-93CH-4946991
TD Cowen has lowered its price target for Orthofix Medical (NASDAQ: OFIX) shares to $9.00 from $12.00, while maintaining a Hold rating, due to missed third-quarter expectations and anticipated supply issues extending into 2027. The stock has seen a significant decline, but InvestingPro analysis suggests it may be undervalued with a Fair Value of $12.30, and analysts forecast profitability this year. Orthofix also reported a narrower-than-expected Q3 loss per share but missed revenue forecasts, leading to a reduced full-year outlook.

Orthofix Q3 Revenue Misses Estimates by $2.62 Million as EPS Beats

https://www.tokenpost.com/news/business/52908
Orthofix Medical Inc. reported third-quarter revenue of $207.9 million, missing analyst estimates by $2.62 million, despite a 1.1% year-over-year increase. The company's GAAP loss per share of $0.15 was 12 cents better than expected. Cash and cash equivalents decreased sequentially to $86.9 million from $104.4 million due to working-capital timing.

Orthofix net sales up 1% to 207.9M in Q3 2026

https://medicalbuyer.co.in/orthofix-net-sales-up-1-to-207-9m-in-q3-2026/
Orthofix Medical Inc. reported a 1.1% increase in net sales to $207.9 million for Q3 2026, driven by growth in Limb Reconstruction and Therapeutic Solutions, despite weaker Spine performance. The company also revised its full-year 2026 net sales guidance down to $825 million to $830 million and non-GAAP adjusted EBITDA to $86 million to $88 million, citing actions to strengthen commercial execution in the Spine segment.

Orthofix Medical Q3 2026 Earnings Call Transcript

https://www.benzinga.com/news/26/11/63032016/orthofix-medical-q3-2026-earnings-call-transcript
Orthofix Medical reported Q3 2026 net sales of $207.9 million, a 2.3% year-over-year increase, driven by strong performance in Limb Reconstruction and Therapeutic Solutions, despite challenges in the U.S. Spine segment due to market softness and supplier delays. The company updated its full-year 2026 guidance, focusing on strategic initiatives to improve U.S. Spine execution, simplify its product portfolio, and invest in high-growth areas while navigating temporary regulatory impacts from European MDR strategy. Management remains committed to disciplined execution and long-term value creation.

Orthofix Medical Releases Q3 2026 Financial Results

https://news.alphastreet.com/orthofix-medical-releases-q3-2026-financial-results/amp/
Orthofix Medical Inc. reported mixed financial results for Q3 2026, with a net loss of $0.15 per share, exceeding Wall Street expectations, while revenue of $207.9M fell slightly short of analyst projections. Despite missing revenue consensus by 1.3%, the figure still marked a 1.1% increase from the previous year. The company expects full-year revenue between $825.0M and $830.0M, and analysts hold a cautiously optimistic view with mostly buy and hold ratings.
Advertisement

OFIX: Sales grew modestly as Limb Reconstruction gains offset Spine pressures and continued cash burn

https://www.tradingview.com/news/urn:summary_document_report:quartr.com:3960050:0-ofix-sales-grew-modestly-as-limb-reconstruction-gains-offset-spine-pressures-and-continued-cash-burn/
Orthofix Medical Inc. (OFIX) reported a modest 1.1% increase in Q3 sales, reaching an adjusted EBITDA of $26.0M, while net loss narrowed to $6.1M. Strong growth in Global Limb Reconstruction was somewhat offset by challenges in Global Spine due to distributor and supply constraints. The company continues to face cash outflow and legal exposure, which remain key considerations.

Operations used $23.5M over nine months at Orthofix Medical (OFIX), even as its Q3 net loss narrowed.

https://www.stocktitan.net/sec-filings/OFIX/10-q-orthofix-medical-inc-quarterly-earnings-report-cbda85636767.html
Orthofix Medical Inc. (OFIX) reported a narrowed Q3 net loss of $6.1 million, down from $22.8 million in the prior year, with net sales of $207.9 million, up 1.1%. Despite the improved net loss, the company's operating cash flow shifted from a $5.7 million inflow to a $23.5 million use in the first nine months of 2026. Global Limb Reconstruction sales increased significantly by 10.6% for the nine-month period, while Global Spine sales saw a modest 0.6% increase.

ORTHOFIX MEDICAL ($OFIX) Releases Q3 2026 Earnings

https://www.quiverquant.com/news/ORTHOFIX+MEDICAL+%28%24OFIX%29+Releases+Q3+2026+Earnings
Orthofix Medical ($OFIX) reported its Q3 2026 earnings, beating EPS estimates by $0.45 with $0.18 per share, but missed revenue estimates by $6.9 million, reporting $207.8 million. The article also details recent insider trading activity, institutional investor holdings, and analyst ratings, with a median price target of $17.0 for the stock.

Orthofix Medical Reports Q3 2026 Financial Results and Details Non-GAAP Metrics in November 9 SEC Filing

https://kalkinemedia.com/us/news/announcements/orthofix-medical-reports-q3-2026-financial-results-and-details-non-gaap-metrics-in-november-9-sec-filing
Orthofix Medical Inc. (NASDAQ: OFIX) filed an 8-K report on November 9, 2026, disclosing its financial results for the third quarter ended September 30, 2026. The company utilized seven non-GAAP metrics, including Adjusted EBITDA, which is highlighted as the primary metric for managing the business. Recurring adjustments include costs related to the January 2023 SeaSpine merger and operating losses from the discontinued M6 artificial disc product lines.

Orthofix Medical Inc. (OFIX) Stock Price, News, Quote & History

https://ca.finance.yahoo.com/quote/OFIX/
This Yahoo Finance page provides a comprehensive overview of Orthofix Medical Inc. (OFIX) stock, including its real-time price, recent trading activity, and key financial statistics. It also highlights an upcoming Q3 2026 earnings call and offers links to news, charts, community discussions, and historical data for the company. The page serves as a central hub for investors to track OFIX's performance and related information.
Advertisement

At $9.07 a share, Orthofix Medical (OFIX) executive Patrick Fisher sells 150 shares.

https://www.stocktitan.net/sec-filings/OFIX/form-4-orthofix-medical-inc-insider-trading-activity-573c820e7ddd.html
Orthofix Medical Inc.'s President, Global Limb Recon, Patrick Fisher, sold 150 shares of common stock at $9.07 per share on November 2, 2026. This transaction was executed under a Rule 10b5-1 trading plan adopted on May 29, 2026. Following the sale, Fisher's reported holdings include 50,769 shares, which account for 36,028 previously reported restricted stock units.

Precision Trading with Orthofix Medical Inc. (OFIX) Risk Zones

https://news.stocktradersdaily.com/news_release/14/Precision_Trading_with_Orthofix_Medical_Inc._OFIX_Risk_Zones_110226084602_1793670362.html
This article provides an in-depth analysis of Orthofix Medical Inc. (OFIX) using AI models to generate trading strategies. It highlights near-term weak sentiment testing mid-term strength within a broader long-term weak bias, noting an exceptional 71.5:1 risk-reward setup. The report outlines specific entry, target, and stop-loss zones for position trading, momentum breakout, and risk hedging strategies.

Orthofix Medical | 4: Statement of changes in beneficial ownership of securities-Officer Fisher Patrick

https://www.moomoo.com/news/notice/308079419/orthofix-medical-4-statement-of-changes-in-beneficial-ownership-of
This document is a Statement of changes in beneficial ownership of securities (Form 4) for Orthofix Medical, specifically pertaining to Officer Fisher Patrick. It indicates a change in the beneficial ownership of securities for this individual.

Orthofix Medical Inc. Estimates – NASDAQ:OFIX

https://www.tradingview.com/symbols/NASDAQ-OFIX/financials-estimates/?category=cash_flow
This article provides a link to the financial estimates for Orthofix Medical Inc. (NASDAQ: OFIX) on TradingView. It offers access to reported financial data and analyst estimates across various statements and valuation metrics, allowing users to compare actual results with estimates and visualize trends.

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duties by Certain Officers and Directors of Orthofix Medical Inc. (NASDAQ: OFIX)

https://www.prnewswire.com/news-releases/shareholder-alert-levi--korsinsky-llp-notifies-shareholders-of-an-investigation-concerning-possible-breaches-of-fiduciary-duties-by-certain-officers-and-directors-of-orthofix-medical-inc-nasdaq-ofix-302915839.html
Levi & Korsinsky, LLP has initiated an investigation into Orthofix Medical Inc. (NASDAQ: OFIX) concerning potential breaches of fiduciary duties by certain officers and directors. Current shareholders of OFIX are encouraged to seek additional information regarding their rights. The firm specializes in securities litigation and aims to recover damages for aggrieved investors.
Advertisement

Investigation launched into Orthofix Medical for possible fiduciary breaches affecting shareholders.

https://pluang.com/en/news-feed/pemberitahuan-pemegang-saham-penyelidikan-orthofix-medical
Levi & Korsinsky has initiated an investigation into Orthofix Medical Inc. concerning potential breaches of fiduciary duties, which could affect current shareholders due to claims of financial misconduct. This scrutiny highlights corporate governance concerns and may result in legal action or compensation for shareholders. The article also provides a market snapshot for the health sector, noting movers like Illumina, Inc. and Bruker Corporation.

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duties by Certain Officers and Directors of Orthofix Medical Inc. (NASDAQ: OFIX)

https://www.morningstar.com/news/pr-newswire/20261021ny78089/shareholder-alert-levi-korsinsky-llp-notifies-shareholders-of-an-investigation-concerning-possible-breaches-of-fiduciary-duties-by-certain-officers-and-directors-of-orthofix-medical-inc-nasdaq-ofix
Levi & Korsinsky, LLP has initiated an investigation into Orthofix Medical Inc. (NASDAQ: OFIX) regarding potential breaches of fiduciary duties by certain officers and directors. Current shareholders of OFIX are encouraged to seek additional information about this investigation. The firm, with extensive experience in securities litigation, offers to provide details to affected investors at no cost.

Orthofix Medical stock sits 41.79 percent below its yearly high with USD 399.8 million value

https://www.ad-hoc-news.de/boerse/news/nebenwerte/orthofix-medical-stock-sits-41-79-percent-below-its-yearly-high-with-usd-399-8-million-value/70377301
Orthofix Medical's stock, trading at EUR 8.83, currently holds a market value of USD 399.8 million, sitting 41.79% below its yearly high. Analysts have a consensus Hold rating with an average 12-month target of USD 14.75, which is above its recent share price. Despite raising its full-year guidance, the company reported a Q2 2026 adjusted loss per share of USD 0.39 and negative operating cash flow, highlighting the importance of future profitability and cash generation.

Orthofix Medical stock sits 41.79 percent below its yearly high with USD 399.8 million value

https://www.ad-hoc-news.de/boerse/news/nebenwerte/orthofix-medical-stock-sits-41-79-percent-below-its-yearly-high-with-usd/70377301
Orthofix Medical (OFIX) had a market capitalization of USD 399.8 million on October 20, 2026, with its stock trading at EUR 8.83. The stock is currently closer to its 52-week low than its high, sitting 41.79% below its yearly peak. Analysts maintain a consensus Hold rating with an average target of USD 14.75, which is above the current share price, but the company faces challenges with negative operating cash flow.

Five analysts set USD 14.75 target for Orthofix Medical stock

https://www.ad-hoc-news.de/boerse/news/nebenwerte/five-analysts-set-usd-14-75-target-for-orthofix-medical-stock/70332598
Five analysts have set a consensus target of USD 14.75 for Orthofix Medical (OFIX) stock, according to a MarketBeat report from October 11, 2026. This target is 54.45% above the current Nasdaq quote of USD 9.55. The company is expected to release its Q3 2026 results on November 3, 2026, with revenue estimates of USD 210.69 million.
Advertisement

Did Orthofix Medical Inc. Insiders Breach their Fiduciary Duties to Shareholders?

https://www.morningstar.com/news/pr-newswire/20261013ny71111/did-orthofix-medical-inc-insiders-breach-their-fiduciary-duties-to-shareholders
Halper Sadeh LLC, an investor rights law firm, is investigating whether officers and directors of Orthofix Medical Inc. (NASDAQ: OFIX) breached their fiduciary duties to shareholders. The firm encourages long-term shareholders to contact them to discuss potential corporate governance reforms, the return of funds to the company, or other relief. Shareholder involvement is highlighted as crucial for improving company practices and enhancing shareholder value.

Orthofix pays former executives $24M in damages

https://finance.yahoo.com/markets/stocks/articles/orthofix-pays-former-executives-24m-165518222.html
Orthofix Medical has paid approximately $24 million in damages to its former CEO, CFO, and CLO after their abrupt "for cause" terminations in 2023. Litigation revealed that an arbitrator ruled in favor of the former executives, finding that the alleged misconduct (offensive text messages) largely predated their severance agreements, thus invalidating the "for cause" termination argument. While the arbitrator acknowledged the inappropriate nature of the texts, the ruling highlighted a contractual timing issue, leading to significant payouts for the former leadership.

Investigation launched into Orthofix Medical for possible fiduciary breaches affecting shareholders

https://pluang.com/en/news-feed/peringatan-pemegang-saham-penyelidikan-orthofix-medical
Levi & Korsinsky law firm has launched an investigation into Orthofix Medical Inc. concerning potential breaches of fiduciary duties by its management. This probe could affect current shareholders and addresses concerns about corporate governance and investor protection. Shareholders are offered free legal assistance and information from the firm.

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duties by Certain Officers and Directors of Orthofix Medical Inc. (NASDAQ: OFIX)

https://www.prnewswire.com/news-releases/shareholder-alert-levi--korsinsky-llp-notifies-shareholders-of-an-investigation-concerning-possible-breaches-of-fiduciary-duties-by-certain-officers-and-directors-of-orthofix-medical-inc-nasdaq-ofix-302903016.html
Levi & Korsinsky, LLP has initiated an investigation into Orthofix Medical Inc. (NASDAQ: OFIX) regarding potential breaches of fiduciary duties by its officers and directors. Current shareholders of OFIX are encouraged to seek additional information or contact the firm to learn more about the ongoing investigation. The firm specializes in securities litigation and aims to recover losses for aggrieved shareholders.

Canaccord cuts target for Orthofix Medical stock from USD 18.00 to USD 13.00

https://www.ad-hoc-news.de/boerse/news/nebenwerte/canaccord-cuts-target-for-orthofix-medical-stock-from-usd-18-00-to-usd-13-00/70266369
Canaccord Genuity has reduced its price target for Orthofix Medical (OFIX) stock from $18.00 to $13.00, while maintaining a Buy rating. This adjustment aligns Canaccord's target with Stifel's previous assessment, both now at $13.00. The stock is currently trading near the lower end of its 52-week range, with its next earnings report scheduled for November 3, 2026.
Advertisement

Canaccord cuts target for Orthofix Medical stock from USD 18.00 to USD 13.00

https://www.ad-hoc-news.de/boerse/news/nebenwerte/canaccord-cuts-target-for-orthofix-medical-stock-from-usd-18-00-to-usd/70266369
Canaccord Genuity has lowered its price target for Orthofix Medical (OFIX) stock from USD 18.00 to USD 13.00, while maintaining a "Buy" rating. This adjustment aligns their target with that of Stifel, which also holds a USD 13.00 target. The article notes recent insider selling and the upcoming earnings report on November 3, 2026, as key events for the stock.

Orthofix Medical's Patrick Fisher Sells 150 Shares Under Rule 10b5-1 Plan

https://kalkinemedia.com/us/news/announcements/orthofix-medicals-patrick-fisher-sells-150-shares-under-rule-10b5-1-plan
Patrick Fisher, President of Global Limb Recon at Orthofix Medical Inc. (NASDAQ: OFIX), sold 150 shares of common stock on October 1, 2026, at $9.44 per share. This transaction was executed under a Rule 10b5-1 trading plan established on May 29, 2026. Following the sale, Fisher beneficially owns 50,919 shares, which includes previously reported restricted stock units.

Insider Sell: President, Global Limb Recon Patrick Fisher Sells 150 Shares of Orthofix Medical Inc (OFIX)

https://www.gurufocus.com/news/9110314/insider-sell-president-global-limb-recon-patrick-fisher-sells-150-shares-of-orthofix-medical-inc-ofix
Patrick Fisher, President, Global Limb Recon at Orthofix Medical Inc (OFIX), sold 150 shares of the company on October 1, 2026. This transaction is part of a larger trend of insider selling at Orthofix, with 17 insider sells against 4 insider buys over the past year. The stock is currently flagged as a "Possible Value Trap, Think Twice" by GuruFocus's GF Value, trading at $9.44 against an intrinsic value of $13.97.

150 shares sold under a trading plan by Patrick Fisher at Orthofix Medical (OFIX).

https://www.stocktitan.net/sec-filings/OFIX/form-4-orthofix-medical-inc-insider-trading-activity-4ec85a8e372f.html
Patrick Fisher, President, Global Limb Recon at Orthofix Medical Inc. (OFIX), sold 150 shares of common stock at $9.44 per share on October 1, 2026. This transaction was conducted under a Rule 10b5-1 trading plan adopted on May 29, 2026. After the sale, Fisher's direct holdings in Orthofix Medical Inc. amount to 50,919 shares, which includes 36,028 previously reported restricted stock units.

Orthofix raises sales guidance: Orthofix Medical stock sits 46.50 percent below its high

https://www.ad-hoc-news.de/boerse/news/nebenwerte/orthofix-raises-sales-guidance-orthofix-medical-stock-sits-46-50-percent-below-its-high/70228991
Orthofix Medical (OFIX) has increased its 2026 net sales guidance to $845 million-$855 million, following second-quarter progress and a European distributor arrangement. Despite the positive outlook, the stock was trading at $9.09 on October 2, 2026, which is 46.50% below its 52-week high of $16.99. Analysts at Stifel maintained a Buy rating with a $13.00 price target, citing profitable growth opportunities for the medical device issuer.
Advertisement

Orthofix Medical stock reports USD 210.93 million revenue

https://www.ad-hoc-news.de/boerse/news/nebenwerte/orthofix-medical-stock-reports-usd-210-93-million-revenue/70201541
Orthofix Medical (OFIX) reported second-quarter 2026 revenue of USD 210.93 million, exceeding forecasts, despite an adjusted EPS loss of USD 0.39. Stifel maintained its USD 13.00 price target and Buy rating, citing profitable growth and commercial execution. The company raised its full-year sales and adjusted EBITDA guidance due to improved sales trends and Medicare reimbursement benefits, though profitability remains a key challenge.

Form 4 Orthofix Medical Inc For: 27 September By Investing.com

https://ng.investing.com/news/stock-market-news/form-4-orthofix-medical-inc-for-27-september-93CH-2710810
This article from Investing.com is a regulatory filing update, specifically a Form 4 for Orthofix Medical Inc., dated September 27. It provides no further details about the filing's content. The rest of the page is filled with various market data, news headlines, and promotional content from Investing.com.

Juniper investment company sells $2.73m of Orthofix Medical shares By Investing.com

https://ng.investing.com/news/stock-market-news/juniper-investment-company-sells-273m-of-orthofix-medical-shares-93CH-2710916
Juniper Investment Company, a 10% owner and director of Orthofix Medical Inc. (NASDAQ:OFIX), recently sold 310,000 shares of common stock for approximately $2.73 million across two transactions in September 2026. Despite the sell-off, Orthofix Medical's stock has seen an 8.4% gain in the past week, though it remains down 38% year-to-date. Analysts believe the stock is undervalued and predict profitability this year, following a stronger-than-expected Q2 2026 performance and raised guidance.

Juniper investment company sells $2.73m of Orthofix Medical shares By Investing.com

https://www.investing.com/news/insider-trading-news/juniper-investment-company-sells-273m-of-orthofix-medical-shares-93CH-4918965
Juniper Investment Company, a major owner and director of Orthofix Medical Inc. (NASDAQ:OFIX), recently sold 310,000 shares of the company's common stock for approximately $2.73 million across two transactions in September 2026. Despite these sales, the stock has shown an 8.4% gain in the past week, though it remains down 38% year-to-date. InvestingPro analysis suggests Orthofix is currently undervalued and poised for profitability this year, following a stronger-than-expected Q2 2026 financial performance.

Form 4 Orthofix Medical Inc For: 27 September By Investing.com

https://au.investing.com/news/stock-market-news/form-4-orthofix-medical-inc-for-27-september-93CH-4660318
This article reports on the filing of Form 4 by Orthofix Medical Inc. for September 27. It appears to be a standard financial news brief from Investing.com, providing basic information about the SEC filing for the company.
Advertisement

Juniper investment company buys $2.73m in Orthofix shares By Investing.com

https://www.investing.com/news/insider-trading-news/juniper-investment-company-buys-273m-in-orthofix-shares-93CH-4918809
Juniper Investment Company, LLC, a major owner and director of Orthofix Medical Inc. (NASDAQ:OFIX), recently purchased 310,000 shares for approximately $2.73 million in mid-September. The stock has since increased by 8.4%, and InvestingPro analysis suggests OFIX remains undervalued with a Fair Value of $12.89. These transactions align with Orthofix's positive Q2 2026 results and raised full-year guidance, despite ongoing challenges with smaller U.S. spine distributors.

Former Orthofix Execs Fired Over Tawdry Texts Awarded $24.5M

https://www.law.com/corpcounsel/2026/09/24/former-orthofix-execs-fired-over-tawdry-texts-awarded-245m/
An arbitrator has awarded $24.5 million to three former Orthofix Medical executives who were fired "for cause" in 2023. The executives were terminated for sending "sophomoric and vulgar text messages among themselves on their private phones." Olshan partner Kyle Bisceglie noted that there was little legal precedent for invoking a "moral turpitude clause" based on private communications that didn't outwardly impact workplace conduct.

A fund bought Orthofix Medical (OFIX) shares twice in September. The second purchase was larger.

https://www.stocktitan.net/sec-filings/OFIX/form-4-a-orthofix-medical-inc-amended-insider-trading-activity-14cdd6cd72fb.html
Juniper Targeted Opportunity Fund, L.P. acquired shares of Orthofix Medical Inc. (OFIX) twice in September 2026. The fund bought 120,000 shares on September 18 at $8.7393 each, and a larger block of 190,000 shares on September 21 at $8.8599 per share. Juniper Investment Company, along with John A. Bartholdson and Alexis P. Michas, were identified as 10% owners and managing members, disclaiming beneficial ownership except for their pecuniary interests.

[Form 4] Orthofix Medical Inc. Insider Trading Activity

https://www.stocktitan.net/sec-filings/OFIX/form-4-orthofix-medical-inc-insider-trading-activity-01dfe4989383.html
This article details a Form 4 SEC filing by Orthofix Medical Inc. (OFIX) regarding insider trading activity. Juniper Investment Company, LLC, John A. Bartholdson, and Alexis P. Michas are identified as net sellers, disposing of 310,000 shares for a total of $2.73 million. The filing also clarifies the beneficial ownership structure through various Juniper funds and notes that the initial figures might have been corrected in an amended Form 4/A.

Stifel reiterates Orthofix Medical stock rating with $13 target

https://www.investing.com/news/analyst-ratings/stifel-reiterates-orthofix-medical-stock-rating-with-13-target-93CH-4901583
Stifel maintained its Buy rating on Orthofix Medical Inc. (NASDAQ: OFIX) with an unchanged $13.00 price target, citing profitable growth and attractive valuation. The firm highlighted the company's 7D FLASH product benefiting from essential tremor tailwinds and improved commercial execution. Orthofix recently surpassed Q2 2026 earnings expectations, raised its full-year guidance, and secured a European distributor arrangement, despite ongoing challenges with smaller U.S. spine distributors.
Advertisement

Stifel reiterates Orthofix Medical stock rating with $13 target By Investing.com

https://ng.investing.com/news/stock-market-news/stifel-reiterates-orthofix-medical-stock-rating-with-13-target-93CH-2696398
Stifel maintained its Buy rating on Orthofix Medical Inc. (NASDAQ:OFIX) shares with a $13.00 price target, citing profitable growth and attractive valuation. The company's 7D FLASH product and improved commercial execution are key drivers, while InvestingPro Tips predict profitability this year with an EPS forecast of $0.69. Orthofix recently surpassed Q2 2026 expectations, raising full-year guidance due to improved sales and Medicare reimbursement.

Orthofix Medical (OFIX) officer sells shares in preset trading plan

https://www.stocktitan.net/sec-filings/OFIX/form-4-orthofix-medical-inc-insider-trading-activity-e3ad50f25e2c.html
Orthofix Medical Inc. (OFIX) officer Patrick Fisher, President, Global Limb Recon, sold 150 shares of common stock at $9.39 per share on September 1, 2026. This transaction was conducted under a pre-set Rule 10b5-1 trading plan adopted on May 29, 2026. Following the sale, Fisher directly holds 51,069 shares, which include 36,028 restricted stock units.

Orthofix Medical's Patrick Fisher Sells 150 Shares Under Rule 10b5-1 Trading Plan

https://kalkinemedia.com/us/news/announcements/orthofix-medicals-patrick-fisher-sells-150-shares-under-rule-10b5-1-trading-plan
Patrick Fisher, President of Global Limb Recon at Orthofix Medical Inc. (NASDAQ: OFIX), sold 150 shares of company common stock on September 1, 2026, at $9.39 per share. This transaction was executed under a Rule 10b5-1 trading plan established on May 29, 2026. Following the sale, Fisher maintains beneficial ownership of 51,069 shares, including previously reported restricted stock units.

Orthofix Medical (OFIX) Stock Sees Fair Value Cut After Analysts Trim Q2 Outlook

https://finance.yahoo.com/markets/stocks/articles/orthofix-medical-ofix-stock-sees-050703863.html
Analysts have revised down the fair value and price targets for Orthofix Medical (OFIX) stock from US$15 to US$13, citing updated projections for revenue and cash generation, alongside the impact of the MDR transition. Despite the cuts, many analysts maintain a "Buy" or "Outperform" rating, indicating a continued constructive long-term outlook for the company, although specific factors like lower expected cash generation and weaker spine distributor performance contributed to the bearish adjustments.

Orthofix president Patrick Fisher sells $13,066 in stock

https://m.investing.com/news/insider-trading-news/orthofix-president-patrick-fisher-sells-13066-in-stock-93CH-4871602?ampMode=1
Patrick Fisher, President, Global Limb Recon at Orthofix Medical Inc. (NASDAQ: OFIX), sold 1,295 shares of the company's common stock for $13,066 to cover tax withholding obligations for restricted stock units. Following the transaction, Fisher beneficially owns 51,219 shares. This sale comes as Orthofix recently surpassed Wall Street expectations for its second-quarter 2026 earnings and raised its full-year guidance.
Advertisement
Advertisement
Advertisement
Advertisement

Sign Up free to view live trades and discussion forum to make more informed financial decisions. No credit card is required for sign up!
View Daily Trades
Join Discussion

Advertisement
Advertisement
Advertisement
Advertisement